Novo Nordisk 'B'

Novo Nordisk is launching the Wegovy pill for obesity in Germany; demand and preorders are high and doctors are running waiting lists. Studies show about 17% weight loss with the pill, while Eli Lilly’s injection Mounjaro achieves up to 20% and the company plans its own pill, Foundayo. The drugs are expected not to be reimbursed by insurers; the market is seen as lucrative because of the high prevalence of obesity and strong growth expectations. Competition between Novo Nordisk and Eli Lilly is likely to remain intense as more players enter the market and technical developments continue. » Más en wiwo.de

The Novo Nordisk share briefly recovered on Friday after Deutsche Bank cut its rating to sell and lowered the price target to DKK 265, but slid back into negative territory during trading. The rebound is supported by the acceptance of the approval application for the Wegovy tablet in China, which is significant in the race for oral weight-loss drugs. Analysts remain divided: recommendations range from sell to hold, with price targets between DKK 200 and DKK 332. The focus remains on approval progress in China and market dynamics in the diabetes and obesity segments. » Más en finanzen.net

China's regulatory authority has accepted the approval application for Novo Nordisk's Wegovy tablet for review. Wegovy is a GLP-1 medication for appetite control and lowering blood sugar and has already recorded over 5 million prescriptions in the US. Deutsche Bank cut its price target from 290 to 265 DKK and downgraded the stock from hold to sell. The Novo Nordisk share fell in Copenhagen at times by around 1.97 percent to 298.95 DKK. » Más en finanzen.net